表紙
市場調査レポート

混合型脂質異常症:パイプライン製品の分析

Mixed Dyslipidemia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 200976
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
混合型脂質異常症:パイプライン製品の分析 Mixed Dyslipidemia - Pipeline Review, H1 2016
出版日: 2016年05月31日 ページ情報: 英文 69 Pages
概要

血漿コレステロールやトリグリセリド(TG)、およびその双方の上昇、ないしは高比重リポタンパク質(LDL)の水準低下が、脂質異常症を引き起こす原因となっています。そして、コレステロールとTGの両方の上昇が、混合型脂質異常症と呼ばれています。TGの水準上昇は急性膵炎の発症につながります。また、LDLの水準上昇は、眼瞼黄色腫や角膜輪、アキレス腱・肘・膝・中手指節関節の腱黄色腫の要因となります。この疾患の病因には、様々な一次的要因(遺伝性)や二次的要因(生活慣習)が挙げられます。治療法にはリスク評価や生活習慣の改善(運動、食事改善)、スタチンを用いたLDLコレステロール標的療法などがあります。高水準のTGや低水準のHDLコレステロールに対しては、ニコチン酸で治療します。

当レポートでは、世界各国での混合型脂質異常症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

混合型脂質異常症の概要

治療薬の開発

  • 混合型脂質異常症向けパイプライン製品:概要
  • 混合型脂質異常症向けパイプライン製品:比較分析

各企業で開発中の混合型脂質異常症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

混合型脂質異常症治療薬:開発中の製品の一覧(企業別)

混合型脂質異常症治療薬の開発に従事している企業

  • Amgen Inc.
  • Pfizer Inc
  • Pronova BioPharma ASA
  • Intas Pharmaceuticals Ltd.
  • Catabasis Pharmaceuticals, Inc.
  • Matinas BioPharma, Inc.
  • CymaBay Therapeutics, Inc

混合型脂質異常症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別
  • 薬効分類別

薬剤のプロファイル

  • evolocumab
  • bococizumab
  • INSUPR-001 DR
  • MBX-8025
  • PRC-4016
  • CAT-2003
  • MAT-9001

混合型脂質異常症治療薬:最新の薬剤プロファイル

混合型脂質異常症治療薬:開発が休止状態の製品

混合型脂質異常症治療薬:開発が中止された製品

混合型脂質異常症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8141IDB

Summary

Global Markets Direct's, 'Mixed Dyslipidemia - Pipeline Review, H1 2016', provides an overview of the Mixed Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mixed Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia
  • The report reviews pipeline therapeutics for Mixed Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Mixed Dyslipidemia therapeutics and enlists all their major and minor projects
  • The report assesses Mixed Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Mixed Dyslipidemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mixed Dyslipidemia Overview
  • Therapeutics Development
    • Pipeline Products for Mixed Dyslipidemia - Overview
  • Mixed Dyslipidemia - Therapeutics under Development by Companies
  • Mixed Dyslipidemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Mixed Dyslipidemia - Products under Development by Companies
  • Mixed Dyslipidemia - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • CymaBay Therapeutics, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Matinas BioPharma Holdings, Inc.
    • Pfizer Inc.
    • Thetis Pharmaceuticals LLC
  • Mixed Dyslipidemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • bococizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • evolocumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IONIS-ANGPTL3LRx - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAT-9001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-452 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mixed Dyslipidemia - Recent Pipeline Updates
  • Mixed Dyslipidemia - Dormant Projects
  • Mixed Dyslipidemia - Discontinued Products
  • Mixed Dyslipidemia - Product Development Milestones
    • Featured News & Press Releases
      • May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting
      • Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab
      • Mar 16, 2016: Amgen Wins Patent Case On Repatha (Evolocumab)
      • Nov 18, 2015: NICE issues draft guidance on evolocumab for lipid disorder
      • Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
      • Mar 29, 2014: New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol
      • Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mixed Dyslipidemia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Mixed Dyslipidemia - Pipeline by Amgen Inc., H1 2016
  • Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016
  • Mixed Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Mixed Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016
  • Mixed Dyslipidemia - Pipeline by Pfizer Inc., H1 2016
  • Mixed Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2016
  • Mixed Dyslipidemia - Dormant Projects, H1 2016
  • Mixed Dyslipidemia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Mixed Dyslipidemia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top